Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | FcRH5 & GPRC5D bispecific antibodies: antigen targets beyond BCMA for multiple myeloma

Carlyn Tan • 9 Jun 2023
EHA 2023
Multiple Myeloma Antibodies Cevostamab Talquetamab

Carlyn Tan, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, briefly discusses the ongoing research on bispecific antibodies for multiple myeloma, focusing on alternative antigen targets beyond BCMA. Dr Tan comments on two promising drugs: cevostamab which targets FcRH5, and talquetamab, which targets GPRC5D. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Janssen – research funding, advisory board
Sanofi – advisory board
Takeda – research funding

More from Carlyn Tan

1:33
Teclistamab for multiple myeloma in US hospitals: real-world data analysis
Carlyn Tan • 9 Dec 2023
0:45
MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myeloma
Carlyn Tan • 9 Jun 2023
0:58
MajesTEC-4 & MagnetisMM-7: BsAb maintenance in NDMM with teclistamab & elranatamab
Carlyn Tan • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals